Loading...
Uploaded by MedPageToday on Oct 28, 2009
http://www.medpagetoday.comSAN FRANCISCO -- Increasing the dose of intravitreal bevacizumab (Avastin) doesn't improve outcomes for central retinal vein occlusion, researchers found.
News & Politics
Standard YouTube License
Load more suggestions
Link to this comment:
All Comments (0)